Pascal Joly focuses on Internal medicine, Dermatology, Psoriasis, Pathology and Surgery. His biological study spans a wide range of topics, including Gastroenterology and Oncology. His Dermatology study integrates concerns from other disciplines, such as Paraneoplastic pemphigus, Bullous pemphigoid and Disease.
His study in the fields of Psoriatic arthritis under the domain of Psoriasis overlaps with other disciplines such as Risk assessment. His work on Lymphoma, Lymph and Cutaneous lymphoma as part of general Pathology study is frequently linked to Plasmacytoid dendritic cell, therefore connecting diverse disciplines of science. Within one scientific family, Pascal Joly focuses on topics pertaining to Confidence interval under Surgery, and may sometimes address concerns connected to Odds ratio, Risk factor and Immunopathology.
His primary scientific interests are in Dermatology, Internal medicine, Pathology, Immunology and Pemphigus. His Dermatology research includes elements of Bullous pemphigoid and Disease. Pascal Joly interconnects Gastroenterology, Surgery and Oncology in the investigation of issues within Internal medicine.
His work carried out in the field of Pemphigus brings together such families of science as Pemphigus vulgaris, Autoimmune disease, Prednisone, Rituximab and Paraneoplastic pemphigus. He focuses mostly in the field of Pemphigus vulgaris, narrowing it down to matters related to Pemphigus foliaceus and, in some cases, Desmoglein 1. Pascal Joly has included themes like Systematic review and Physical therapy in his Psoriasis study.
Internal medicine, Dermatology, Pemphigus, Rituximab and Immunology are his primary areas of study. His Internal medicine study combines topics in areas such as Gastroenterology and Psoriasis. His Dermatology research is multidisciplinary, incorporating perspectives in Paraneoplastic pemphigus, Mycosis fungoides and Incidence.
His Pemphigus research incorporates themes from Corticosteroid, Pemphigoid and Pemphigus vulgaris. His Rituximab study combines topics from a wide range of disciplines, such as Tumor necrosis factor alpha, Regimen, B cell and Prednisone. His work on Desmoglein, Autoantibody, Antibody and Bullous pemphigoid is typically connected to Drug reaction with eosinophilia and systemic symptoms as part of general Immunology study, connecting several disciplines of science.
The scientist’s investigation covers issues in Internal medicine, Pemphigus, Rituximab, Pemphigus vulgaris and Gastroenterology. The various areas that Pascal Joly examines in his Pemphigus study include B cell, 2019-20 coronavirus outbreak, Venereology and Virology. His study looks at the intersection of Rituximab and topics like Prednisone with Regimen.
His Pemphigus vulgaris study is related to the wider topic of Dermatology. His Dermatology research is multidisciplinary, incorporating elements of Cross-sectional study and Hidradenitis suppurativa. His Bullous pemphigoid research incorporates elements of Epidermolysis bullosa, Mucous membrane and Pathology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid
Pascal Joly;Jean-Claude Roujeau;Jacques Benichou;Catherine Picard.
The New England Journal of Medicine (2002)
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Corine Bertolotto;Fabienne Lesueur;Sandy Giuliano;Thomas Strub.
Nature (2011)
A Single Cycle of Rituximab for the Treatment of Severe Pemphigus
Pascal Joly;Hugo Mouquet;Jean-Claude Roujeau;Michel D'Incan.
The New England Journal of Medicine (2007)
High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL
Alisa M. Goldstein;May Chan;Mark Harland;Elizabeth M. Gillanders.
Cancer Research (2006)
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Pascal Joly;Maud Maho-Vaillant;Catherine Prost-Squarcioni;Vivien Hebert.
The Lancet (2017)
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Multiorgan Antiviral T Cell Response
Damien Picard;Baptiste Janela;Vincent Descamps;Michel D’Incan.
Science Translational Medicine (2010)
Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review.
C. Horreau;C. Pouplard;E. Brenaut;T. Barnetche.
Journal of The European Academy of Dermatology and Venereology (2013)
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review.
Tony Petrella;Martine Bagot;Rein Willemze;Marie Beylot-Barry.
American Journal of Clinical Pathology (2005)
Incidence and Mortality of Bullous Pemphigoid in France
Pascal Joly;Sophie Baricault;Agnès Sparsa;Philippe Bernard.
Journal of Investigative Dermatology (2012)
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases
B Vergier;A de Muret;M Beylot-Barry;L Vaillant.
Blood (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Federal University of Toulouse Midi-Pyrénées
Université Paris Cité
Université Paris Cité
Université Paris Cité
Université Paris Cité
Grenoble Alpes University
University of Lübeck
University of Pennsylvania
Bambino Gesù Children's Hospital
University of Nantes
University of Western Ontario
Huazhong University of Science and Technology
Missouri University of Science and Technology
Nanchang Hangkong University
Tongji University
Oregon Health & Science University
University of Copenhagen
German Center for Lung Research
University of Georgia
Dartmouth College
Woods Hole Oceanographic Institution
Imperial College London
University of Alberta
Jönköping University
Karolinska University Hospital
Universität Hamburg